I’ve spent 11 years in pharma commercial strategy, and I have a running list of "meetings that look big but do nothing for adoption." It’s a long list. Every year, I watch teams scramble to secure the biggest booth at ASCO, hire the most expensive PR firms to announce "practice-changing data," and then—silence. Six months later, the prescribing trends haven't moved, the formulary status is stuck in committee, and the market share remains flat.
The problem isn't the data. It's the assumption that "presence" equals "influence." If you want your practice-changing data to actually move the needle on oncology prescribing trends for the next three to five years, you have to stop treating conferences like brand awareness exercises and start treating them like launch milestones.
The Anatomy of Influence: Why ASCO is the North Star
ASCO isn’t just a meeting; it is the industry’s central nervous system. When a major study is presented, the ripples aren’t just felt in the plenary hall. They travel through the medical community, hit the clinical guidelines (NCCN), eventually trickle into the Health System P&T committees, and finally reach the desk of the community oncologist.
The reason ASCO data has such a long tail is that it creates a worldpharmatoday new "clinical truth." Once a survival curve is shown on that big screen, it becomes the baseline against which every competitor is measured. If you aren't ready to frame your narrative within that new reality the second the abstract drops, you’ve already lost the launch.
Stop Choosing Conferences for the "Hype"—Choose Them for the Goal
Most commercial teams build their event portfolio based on where they went last year. This is a fatal error. Before you commit budget or personnel to any conference, you need a clear answer to: "What specific commercial decision does this meeting force?"
A Framework for Event Selection
Stop asking "Is this event important?" and start asking "What does this event unlock?"
The Summer Anchor: Why BIO is a Strategic Play
I often hear commercial leaders dismiss the BIO Partnering platform as "the BD team's problem." This is short-sighted. Your commercial success is tied to the strength of your pipeline and your strategic positioning against your competitors.
BIO is where you assess the "Competitive Intelligence" of the future. By observing who is partnering with whom, you gain a massive lead-time on the next wave of combination therapies or platform technologies. If your competitors are licensing an asset that addresses a gap in their current portfolio, you need to know now—not when the phase III trial hits ASCO in three years. Use the partnering platform to track the movement of competitors’ portfolios to adjust your commercial long-game.
The Execution Gap: Fierce Pharma Week
Once the clinical data is out, the battle shifts to commercial execution. This is where events like Fierce Pharma Week become vital. You aren't there for the clinical data; you are there to stress-test your commercial narrative. Can you explain your ASCO abstracts impact to a room of peers without using marketing jargon? If you can’t, your field force won't be able to explain it to a busy oncologist.
Use these events to pressure-test your messaging. If the internal strategy doesn't hold up under the scrutiny of industry peers, it certainly won't hold up in a high-pressure physician interaction.
The Reality Check: The Health Management Academy (THMA)
Here is where many teams fail: They win the battle of clinical evidence (ASCO) but lose the war of formulary reality. You can have the most compelling data in the world, but if the health system doesn't believe the drug is operationally sustainable, you won't get the script.
The Health Management Academy (THMA) forums are essential for bridging this gap. This isn't about marketing; it’s about understanding the internal hurdles of large health systems. When you sit in these forums, you learn about:
- The staffing shortages affecting your drug's administration. The electronic health record (EHR) integration hurdles that make prescribing difficult. The specific financial incentives that shift oncology prescribing trends within a system.
Checklist: Is your conference strategy actually driving adoption?
If you are planning your event calendar for the next 12 months, run your current list through this simple sanity check. If you can’t answer these, you are likely burning budget on "brand awareness" that won't show up on your Q4 sales report.
The "Outcome" Test: Can I name the one specific commercial pivot this event is meant to inform? (e.g., "Adjusting our value proposition for the second-line setting.") The "ASCO-to-Formulary" Bridge: How does the content we are presenting/consuming at this meeting address an objection raised by a P&T committee? The Intelligence Loop: Do we have a plan to feed the competitor intelligence gathered here back to the brand team within 48 hours? The "Must-Attend" Myth Check: If we didn't attend this meeting, would our market share change by even 0.1% in the next two quarters? If no, cancel the registration.Moving Past "Hand-Wavy" ROI
We need to stop using vague ROI claims. "Brand visibility" and "industry presence" are not KPIs. If you can’t link your conference strategy to a specific change in oncology prescribing trends or a specific movement in your formulary access plan, you are not doing strategy—you are doing travel planning.
The ASCO data is the spark, but the commercial strategy is the fuel. Most teams spend all their time polishing the spark and ignore the fuel. Don’t be that team. Use your events to find out where your clinical data hits the reality of the healthcare system, adjust your narrative based on real intelligence, and stop trying to be everywhere at once.
Pick three meetings. Make them hard to attend, because you’ll be working the entire time. Treat them like field-based research operations. That is how you turn a week in a conference hall into years of market-share growth.